Home » Author Archives: Catherine Skari (page 3)

Author Archives: Catherine Skari

TIF’s latest Newletter is out now!

Catch up with our most recent newsletter and get informed about TIF’S activities and achievements in the past few months! If you would also like to receive our news directly into your inbox, along with thousands of people across the world, subscribe here!

Read More »

Bluebird bio announces 1st commercial launch of ZYNTEGLO™in Germany

  Bluebird bio, Inc. announced earlier today the launch  of ZYNTEGLO™ in Germany,  the company’s one-time gene therapy for patients 12 years and older with transfusion-dependent β-thalassaemia (TDT) who do not have a β0/β0 genotype, for whom haematopoietic stem cell (HSC) transplantation is appropriate but a human leukocyte antigen (HLA)-matched related ...

Read More »

Deferasirox Accord: A new generic of Exjade recommended for approval by the EMA

The Committee for Medicinal Products for Human Use (CHMP), the European Medicines Agency‚ (EMA) committee responsible for human medicines, has recently adopted a positive opinion recommending the granting of a marketing authorisation for the medicinal product Deferasirox Accord, by Accord Healthcare S.L.U.   Deferasirox Accord is a generic of Exjade, ...

Read More »

Delegation Visit to Italy – 15 December 2019

  A Symposium on the ‚Diagnosis and Treatment of Chronic Liver Disease and Disturbances in Heart Rhythm in Haemoglobinopathies‘ was organised by the Associazzione per la Lotta alla Talassemia di Ferrara – Rino Vullo and took place in Ferrara (Italy) on 15th of December 2019. The Symposium was held in ...

Read More »